Risankizumab, a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor (IL-23R) complex, distinguishing it from biological therapies that target the shared IL-12 and IL-23 p40 subunit, is currently approved for the treatment of moderate-to-severe plaque psoriasis in over 70 countries, including the USA, Canada, and Japan and in Europe (11, 12). This evidence concerns the gene IL23R and psoriasis vulgaris.